Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19.
COVID-19
SARS-CoV-2
diabetes mellitus
glucose metabolism disorder
hyperglycemia
obesity
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
14
06
2020
revised:
22
06
2020
accepted:
23
06
2020
pubmed:
27
6
2020
medline:
10
3
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
Identification of risk factors of severe coronavirus disease 2019 (COVID-19) is critical for improving therapies and understanding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis. We analyzed 184 patients hospitalized for COVID-19 in Livingston, New Jersey for clinical characteristics associated with severe disease. The majority of patients with COVID-19 had diabetes mellitus (DM) (62.0%), Pre-DM (23.9%) with elevated fasting blood glucose (FBG), or a body mass index >30 with normal hemoglobin A1c (HbA1C) (4.3%). SARS-CoV-2 infection was associated with new and persistent hyperglycemia in 29 patients, including several with normal HbA1C levels. Forty-four patients required intubation, which occurred significantly more often in patients with DM as compared with non-diabetics. Severe COVID-19 occurs in the presence of impaired glucose metabolism in patients, including those with DM, preDM, and obesity. COVID-19 is associated with elevated FBG and several patients presented with new onset DM or in DKA. The association of dysregulated glucose metabolism and severe COVID-19 suggests that SARS-CoV-2 pathogenesis involves a novel interplay with glucose metabolism. Exploration of pathways by which SARS-CoV-2 interacts glucose metabolism is critical for understanding disease pathogenesis and developing therapies.
Sections du résumé
BACKGROUND
Identification of risk factors of severe coronavirus disease 2019 (COVID-19) is critical for improving therapies and understanding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis. We analyzed 184 patients hospitalized for COVID-19 in Livingston, New Jersey for clinical characteristics associated with severe disease. The majority of patients with COVID-19 had diabetes mellitus (DM) (62.0%), Pre-DM (23.9%) with elevated fasting blood glucose (FBG), or a body mass index >30 with normal hemoglobin A1c (HbA1C) (4.3%). SARS-CoV-2 infection was associated with new and persistent hyperglycemia in 29 patients, including several with normal HbA1C levels. Forty-four patients required intubation, which occurred significantly more often in patients with DM as compared with non-diabetics. Severe COVID-19 occurs in the presence of impaired glucose metabolism in patients, including those with DM, preDM, and obesity. COVID-19 is associated with elevated FBG and several patients presented with new onset DM or in DKA. The association of dysregulated glucose metabolism and severe COVID-19 suggests that SARS-CoV-2 pathogenesis involves a novel interplay with glucose metabolism. Exploration of pathways by which SARS-CoV-2 interacts glucose metabolism is critical for understanding disease pathogenesis and developing therapies.
Identifiants
pubmed: 32589756
doi: 10.1002/jmv.26227
pmc: PMC7361926
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-415Informations de copyright
© 2020 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Diabetes Metab Syndr. 2020 May - Jun;14(3):211-212
pubmed: 32172175
J Med Virol. 2021 Jan;93(1):409-415
pubmed: 32589756
J Med Virol. 2020 Jul;92(7):770-775
pubmed: 32293710
Diabet Med. 2006 Jun;23(6):623-8
pubmed: 16759303
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
Diabetes Care. 2009 May;32(5):828-33
pubmed: 19196895
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Lancet. 2020 May 16;395(10236):1544-1545
pubmed: 32380044
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Acta Diabetol. 2010 Sep;47(3):193-9
pubmed: 19333547
Int J Mol Sci. 2017 Mar 05;18(3):
pubmed: 28273875
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Diabet Med. 2020 May;37(5):723-725
pubmed: 32242990
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
J Diabetes. 2020 Apr;12(4):347-348
pubmed: 32162476